Drug Trial Radar · NCT01459796
Study of the Safety and Efficacy of Long-Term Rilonacept Treatment for the Prevention of Gout Flares
Last checked: Nov 20, 2026Latest source record: Jul 18, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
220
Actual
Start
Nov 2011
Primary completion
Jun 2013
Study completion Jun 2013
Sponsor
- Lead sponsor
- Regeneron PharmaceuticalsRegeneron (REGN)
- Sponsor type
- Industry
- First posted
- Oct 26, 2011
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study was to determine the safety and tolerability of rilonacept for participants with gout who were initiating allopurinol.
Conditions
- Gout
Interventions
RilonaceptDrug
Rilonacept 160 mg loading dose followed by Rilonacept 80 mg/2 mL injections qw for 52 weeks.
PlaceboDrug
Placebo loading dose followed by placebo injections (2 mL) qw for 52 weeks.
AllopurinolDrug
Allopurinol 50 or 100 mg, orally daily for 52 weeks as background treatment.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With Treatment Emergent Adverse Events (TEAEs)Time frame: Day 1 to Day 392 (Week 56)
Locations
74 sites in 1 country. Site status is shown where the registry gives one.
Site not named
Birmingham, Alabama
Site not named
Mesa, Arizona
Site not named
Phoenix, Arizona
Site not named
Scottsdale, Arizona
Site not named
Sierra Vista, Arizona
Site not named
Tucson, Arizona
Site not named
Searcy, Arkansas
Site not named
Concord, California
Site not named
La Jolla, California
Site not named
Long Beach, California
Site not named
Whittier, California
Site not named
Denver, Colorado
Site not named
Trumbull, Connecticut
Site not named
Washington D.C., District of Columbia
Site not named
Clearwater, Florida
Site not named
DeLand, Florida
Site not named
Delray Beach, Florida
Site not named
New Port Richey, Florida
Site not named
Ocala, Florida
Site not named
Orlando, Florida
Site not named
St. Petersburg, Florida
Site not named
Tampa, Florida
Site not named
Venice, Florida
Site not named
Atlanta, Georgia
Site not named
Boise, Idaho
Site not named
Coeur d'Alene, Idaho
Site not named
Meridian, Idaho
Site not named
Avon, Indiana
Site not named
Brownsburg, Indiana
Site not named
Evansville, Indiana
Site not named
Bowling Green, Kentucky
Site not named
Elizabethtown, Kentucky
Site not named
Owensboro, Kentucky
Site not named
New Orleans, Louisiana
Site not named
Cumberland, Maryland
Site not named
Hagerstown, Maryland
Site not named
Wheaton, Maryland
Site not named
Fall River, Massachusetts
Site not named
Edina, Minnesota
Site not named
St Louis, Missouri
Showing 40 of 74 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.